{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:35:35Z","timestamp":1773326135739,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T cells can be divided into two major subtypes based on which chains that make up the T cell receptor (TCR): the conventional \u03b1\u03b2 T cells and the less common \u03b3\u03b4 T cells. \u03b3\u03b4 T cells are attractive targets of cancer immunotherapy due to e.g. their independence from MHC-restricted activation. Despite the successful implementation of immune checkpoint inhibitors for the treatment of metastatic melanoma, not all patients respond favorably to the treatment. In this study we characterized \u03b3\u03b4 T cells in peripheral blood from patients with cutaneous and uveal melanoma, and from age-matched healthy controls, with ultrasensitive DNA sequencing (SiMSen-Seq) of the \u03b4-chain and flow cytometry to facilitate the introduction of \u03b3\u03b4 T cell-based treatment strategies. As a general trend, the V\u03b41<jats:sup>+<\/jats:sup> subpopulation was found to be more abundant in patients labeled as responders versus non-responders. Regarding clonal diversity, although a high oligoclonality was found in each individual and within each group, clonal diversity was lower in patients labeled as responders to treatment. Cutaneous melanoma patients had a larger total number of clonotypes compared to the healthy controls, and did also express higher levels of the receptor NKG2D on the surface of V\u03b42<jats:sup>+<\/jats:sup> cells. Overall, we could see small differences between cutaneous and uveal melanoma patients and healthy controls in regard to distribution of \u03b3\u03b4 subpopulations, with high clonal diversities and a mostly private repertoire of the \u03b4 receptor among all groups.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1564333","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:30:44Z","timestamp":1753680644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular and molecular characterization of \u03b3\u03b4 T cells in peripheral blood from patients with metastases from cutaneous and uveal melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Tamara","family":"Alonso-Agudo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"St\u00e5hlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B2","article-title":"Cancer i siffror 2023","year":"2023"},{"key":"B3","article-title":"The eye","volume-title":"Robbins and Cotran pathologic basis of disease","author":"Folberg","year":"2015"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00452-4","article-title":"gammadelta T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nri3904","article-title":"gammadelta T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of gammadelta T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.06.001","article-title":"Proportions of blood-borne Vdelta1+ and Vdelta2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab","volume":"64","author":"Wistuba-Hamprecht","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae023","article-title":"Tumor-infiltrating gammadelta T cells as targets of immune checkpoint blockade in melanoma","volume":"115","author":"Di Simone","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00690-0","article-title":"PD-1 defines a distinct, functional, tissue-adapted state in Vdelta1(+) T cells with implications for cancer immunotherapy","volume":"5","author":"Davies","year":"2024","journal-title":"Nat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040800","article-title":"Human gammadelta TCR repertoires in health and disease","volume":"9","author":"Fichtner","year":"2020","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa159","article-title":"Ultrasensitive DNA immune repertoire sequencing using unique molecular identifiers","volume":"66","author":"Johansson","year":"2020","journal-title":"Clin Chem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101253","DOI":"10.1016\/j.mam.2024.101253","article-title":"Principles of digital sequencing using unique molecular identifiers","volume":"96","author":"Andersson","year":"2024","journal-title":"Mol Aspects Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2960","article-title":"Towards error-free profiling of immune repertoires","volume":"11","author":"Shugay","year":"2014","journal-title":"Nat Methods"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.6599744","article-title":"Immunomind\/immunarch: immunarch 0.6.9 (0.6.9)","author":"Popov","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.2.452","article-title":"Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells","volume":"167","author":"Anegon","year":"1988","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200940257","article-title":"CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC","volume":"40","author":"Maggi","year":"2010","journal-title":"Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)34459-4","article-title":"Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters","volume":"257","author":"Castagna","year":"1982","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.143.4.1283","article-title":"Mechanisms of T cell activation by the calcium ionophore ionomycin","volume":"143","author":"Chatila","year":"1989","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1601483","DOI":"10.1080\/2162402X.2019.1601483","article-title":"The features of circulating and tumor-infiltrating gammadelta T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome","volume":"8","author":"Girard","year":"2019","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149570","article-title":"Skewed differentiation of circulating V\u03b39V\u03b42 T lymphocytes in melanoma and impact on clinical outcome","volume":"11","author":"Toia","year":"2016","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2011.02524.x","article-title":"Impaired function of gamma-delta lymphocytes in melanoma patients","volume":"41","author":"Petrini","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ijc.29818","article-title":"Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic Malignant melanoma","volume":"138","author":"Wistuba-Hamprecht","year":"2016","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1080","article-title":"gammadelta T cells in cancer: a small population of lymphocytes with big implications","volume":"8","author":"Raverdeau","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12141.x","article-title":"Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma","volume":"120","author":"Argentati","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.83.9.1069","article-title":"Alpha\/beta- and gamma\/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas","volume":"83","author":"Bialasiewicz","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ni.3686","article-title":"Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection","volume":"18","author":"Ravens","year":"2017","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating gammadelta T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0008-8749(92)90008-D","article-title":"CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes","volume":"143","author":"Braakman","year":"1992","journal-title":"Cell Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.6.2417","article-title":"Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes","volume":"153","author":"Lanier","year":"1994","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2010.00908.x","article-title":"Cytotoxic and non-cytotoxic roles of the CTL\/NK protease granzyme B","volume":"235","author":"Afonina","year":"2010","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2004.06.013","article-title":"Non-peptide antigens activating human Vgamma9\/Vdelta2 T lymphocytes","volume":"95","author":"Poupot","year":"2004","journal-title":"Immunol Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1597","article-title":"Evidence for extrathymic changes in the T cell receptor gamma\/delta repertoire","volume":"171","author":"Parker","year":"1990","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (gammadelta) T cells: friend or foe in cancer development","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.1996.d01-79.x","article-title":"Different percentages of peripheral blood gamma delta + T cells in healthy individuals from different areas of the world","volume":"43","author":"Esin","year":"1996","journal-title":"Scand J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-255166","article-title":"The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation","volume":"116","author":"Knight","year":"2010","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"14760","DOI":"10.1038\/ncomms14760","article-title":"Clonal selection in the human Vdelta1 T cell repertoire indicates gammadelta TCR-dependent adaptive immune surveillance","volume":"8","author":"Davey","year":"2017","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"key":"B42","article-title":"Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma","volume":"38","author":"Blom","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B43","article-title":"Association of HLA class I and class II antigen expression and mortality in uveal melanoma","volume":"42","author":"Ericsson","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0810","article-title":"Expression of classic and nonclassic HLA class I antigens in uveal melanoma","volume":"44","author":"Anastassiou","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(02)00389-0","article-title":"HLA expression in uveal melanoma: there is no rule without some exception","volume":"63","author":"Jager","year":"2002","journal-title":"Hum Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:30:45Z","timestamp":1753680645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1564333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1564333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"1564333"}}